Gilead Sciences (GILD) Profit After Tax Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (3y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
7.74% |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
133.08% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
42.47% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-51.87% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
26.01% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
75.17% |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
712.11% |
| 10 |
Novartis Ag |
108.28 Bn |
107.60 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
26.01% |
| Dec 31, 2025 |
10.59% |
| Sep 30, 2025 |
19.49% |
| Jun 30, 2025 |
19.97% |
| Mar 31, 2025 |
310.57% |
| Dec 31, 2024 |
70.77% |
| Sep 30, 2024 |
-21.52% |
| Jun 30, 2024 |
1.98% |
| Mar 31, 2024 |
-64.13% |
| Dec 31, 2023 |
-3.89% |
| Sep 30, 2023 |
83.24% |
| Jun 30, 2023 |
32.25% |
| Mar 31, 2023 |
-13.08% |
| Dec 31, 2022 |
-15.65% |
| Sep 30, 2022 |
52.29% |
| Jun 30, 2022 |
-15.48% |
| Mar 31, 2022 |
-78.73% |
| Dec 31, 2021 |
392.33% |
| Sep 30, 2021 |
7.32% |
| Jun 30, 2021 |
-5.73% |
